The Oncologic Drugs Advisory Committee (ODAC) reviewed the new drug application (NDA) #211810.
The Oncologic Drugs Advisory Committee (ODAC) reviewed the new drug application (NDA) #211810 for perxidartinib and NDA # 212166 for quizartinib by Daiichi Sankyo on May 14th, 2019. Pexidartinib was evaluated for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adult patients. The intended use of quizartinib was for the treatment of Feline McDonough Sarcoma-like tyrosine kinase 3 internal tandem duplication (FTL3-ITD) positive relapsed or refractory (R/R) acute myeloid leukemia (AML).
Pexidartinib is a tyrosine kinase inhibitor (TKI) that targets the colony stimulating factor (CSF-1) receptor in the synovium of abnormal tumor cells. To demonstrate efficacy and safety, ENLIVEN, a two-part, multicenter, double-blind, randomized, placebo-controlled phase III study was conducted. Phase I and phase II clinical studies were also evaluated.
The morning meeting had 1 discussion question and 1 voting question. The voting question asked whether the benefits of pexidartinib outweigh the risks. It resulted in a positive vote of 12 YES to 3 NO. Those who disagreed were concerned about the potential for improper utilization and increased incidence of liver toxicity.
Quizartinib is a type II tyrosine kinase inhibitor of Feline McDonough Sarcoma-like tyrosine kinase 3 (FLT3) signaling and FLT3-ITD dependent cell proliferation and survival. To demonstrate the efficacy and safety there was one phase I, two phase II, and the QuANTUM-R pivotal phase III study.
The afternoon meeting had 2 discussion questions and 1 main voting question. The voting question asked if the results of QuANTUM-R properly demonstrated that the benefits outweigh the safety risks for patients with R/R FLT-ITD-positive AML. It resulted in a vote of 3 YES and 8 NO. Those in support believed that the potential risk of QT prolongation was not a major concern. However, the majority were not convinced that the benefits demonstrated in QuANTUM-R outweighed the safety risks.
The agency is not obligated to follow its panels’ recommendation, but normally does so.
While the pexidartinib status is pending, on June 21st, Daiichi Sankyo announced it received a Complete Response Letter (CRL) for Quizartinib. This letter addresses the concern and deficiencies that prior to resubmission must be resolved.
ISS has almost two decades of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact email@example.com
This post was authored by Sharon Christian. Sharon is a summer intern at ISS and an undergraduate student at Rutgers University.
Download ISS' Essential Guide to Preparing for a Meeting at the FDA White Oak Campus.
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us